Streetbeat News

Analyst Ratings

KLAC

Cantor Fitzgerald has maintained a Neutral rating on KLA (NASDAQ:KLAC) but has lowered the price target from $950 to $925.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:39 pm

IBM

Goldman Sachs analyst James Schneider has maintained a Buy rating on IBM and raised the price target from $220 to $250.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:36 pm

BEN

Goldman Sachs analyst Alexander Blostein has maintained a 'Sell' rating on Franklin Resources (NYSE:BEN) and lowered the price target from $23.75 to $21.25.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:34 pm

PRTA

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Prothena Corp (NASDAQ:PRTA).

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:34 pm

MKC

McCormick & Company (NYSE:MKC) is set to release its Q3 earnings on Oct. 1, with expectations of increased earnings per share and revenue. The company's dividend yield is currently 2.02%, and investors are considering dividend income strategies. Bank of America has maintained a Buy rating and raised the price target for McCormick.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:33 pm

BAM

Goldman Sachs analyst Alexander Blostein has maintained a Buy rating on Brookfield Asset Management (NYSE:BAM) and increased the price target from $47 to $52.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:31 pm

IPG

T

VZ

Analysts have provided their ratings on three high-dividend yielding stocks in the tech and telecom sectors: Verizon, AT&T, and Interpublic Group. Verizon received a Neutral and a Buy rating with increased price targets, AT&T received Buy ratings with increased price targets, and Interpublic Group received a downgrade and a price target cut.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:30 pm

ARES

Goldman Sachs analyst Alexander Blostein has maintained a Buy rating on Ares Management and increased the price target from $145 to $160.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:29 pm

JNJ

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Johnson & Johnson (NYSE:JNJ) and maintained a price target of $215.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:22 pm

BL

NIO

PRME

Nio shares rise 15% due to a significant investment in its China subsidiary. Prime Medicine enters a strategic collaboration with Bristol Myers Squibb, receiving $110M upfront and potential milestones over $3.5B, boosting its stock by 33%. BlackLine shares increase after a Morgan Stanley upgrade.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm